News

Press Releases:

Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation

June 10, 2020
Orpheris, a subsidiary of Ashvattha, announced results from a Phase 1 single administration study evaluating the subcutaneous (SC) formulation of...

Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients

May 28, 2020
Orpheris, a subsidiary of Ashvattha, announced the FDA has agreed to a Phase 2 clinical study to evaluate the safety,...

Ashvattha Therapeutics to Present at 2020 AACR Virtual Annual Meeting

May 18, 2020
Ashvattha Therapeutic has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in...

Ashvattha Therapeutics Unveils Transformative Dendrimer-based anti-VEGF Treatment for Retinal Diseases at ARVO 2020

May 6, 2020
Company to develop subcutaneously administered dendrimer-based anti-VEGF therapy with selective targeting in wet AMD. Potential therapeutic may offer significant...